Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Average Recommendation of “Hold” by Brokerages

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have been given an average recommendation of “Hold” by the five analysts that are covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $13.75.

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Theravance Biopharma in a report on Tuesday.

Theravance Biopharma Price Performance

NASDAQ TBPH opened at $8.86 on Tuesday. The stock’s 50-day moving average is $9.38 and its 200-day moving average is $8.90. Theravance Biopharma has a one year low of $7.44 and a one year high of $10.90. The firm has a market cap of $435.68 million, a P/E ratio of -8.77 and a beta of 0.21.

Insider Buying and Selling at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 4,000 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 309,565 shares in the company, valued at approximately $2,786,085. This represents a 1.28 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Ballentine Partners LLC acquired a new stake in shares of Theravance Biopharma in the 3rd quarter valued at $104,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Theravance Biopharma by 64.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 3,696 shares during the last quarter. GSA Capital Partners LLP boosted its stake in Theravance Biopharma by 12.6% in the third quarter. GSA Capital Partners LLP now owns 229,780 shares of the biopharmaceutical company’s stock valued at $1,852,000 after buying an additional 25,691 shares in the last quarter. Algert Global LLC bought a new position in Theravance Biopharma in the third quarter valued at about $851,000. Finally, Quantbot Technologies LP acquired a new position in Theravance Biopharma during the third quarter worth about $60,000. 99.10% of the stock is owned by institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.